secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-256101
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director James Collins resigns; Rachel King appointed to board of Fulcrum Therapeutics
--------------------------------------------------------------------------------

- James J. Collins resigned as Class II director effective Nov 12, 2024, not due to any disagreement with the company or board.
- Board appointed Rachel King as Class II director to fill the vacancy; term expires at 2027 annual meeting.
- King is independent and will serve on Compensation & Human Capital Management Committee.
- King receives standard non-employee director compensation including option for 60,000 shares at $3.64 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/d875361d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-256101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer